Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome
Methodological detailsinternational, evidence-based, AGREEII-compliant, GRADE framework, Approved by NHMRC, 58 prioritized clinical questions; 52 systematic and 3 narrative reviews, 39 professional and consumer organizations covering 71 countries
- International
- Evidence-based
- AGREEII-compliant
- GRADE framework
- Approved by NHMRC
- 58 prioritized clinical questions; 52 systematic and 3 narrative reviews
- 39 professional and consumer organizations covering 71 countries
Recommendations
As issued by the authors
Refined individual diagnostic criteria, simplified diagnostic algorithm, and anti-Müllerian hormone (AMH) levels as an alternative to US in adults only
Strengthened recognition of broader features of polycystic ovary syndrome (PCOS): metabolic risk factors, CVD, sleep apnea, very high prevalence of psychological features, high-risk status for adverse pregnancy outcomes
Emphasis on the poorly recognized, diverse burden of disease and need for greater healthcare professional education, evidence-based patient information, improved models of care and shared decision making, alongside greater research
Maintained emphasis on healthy lifestyle, emotional wellbeing and quality of life, with awareness and consideration of weight stigma
Emphasis on evidence-based medical therapy and cheaper and safer fertility management
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →